

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8155350

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ARCHEMIX LLC	08/31/2023
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	IVERIC BIO., INC.
<b>Street Address:</b>	8 SYLVAN WAY
<b>City:</b>	PARSIPPANY
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	07054
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	7538211
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(212)588-0500
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(212) 588-0800
<b>Email:</b>	Docket@haugpartners.com
<b>Correspondent Name:</b>	HAUG PARTNERS LLP
<b>Address Line 1:</b>	745 FIFTH AVENUE
<b>Address Line 2:</b>	10TH FLOOR
<b>Address Line 4:</b>	NEW YORK, NEW YORK 10151
<b>ATTORNEY DOCKET NUMBER:</b>	A112-8.US.1
<b>NAME OF SUBMITTER:</b>	SHABANA ARJUNE
<b>SIGNATURE:</b>	/Shabana Arjune/
<b>DATE SIGNED:</b>	09/07/2023
<b>Total Attachments: 12</b>	
source=Iveric - Archemix - Patent Assignment (FULLY EXECUTED)#page1.tif	
source=Iveric - Archemix - Patent Assignment (FULLY EXECUTED)#page2.tif	
source=Iveric - Archemix - Patent Assignment (FULLY EXECUTED)#page3.tif	
source=Iveric - Archemix - Patent Assignment (FULLY EXECUTED)#page4.tif	
source=Iveric - Archemix - Patent Assignment (FULLY EXECUTED)#page5.tif	

source=Iveric - Archemix - Patent Assignment (FULLY EXECUTED)#page6.tif  
source=Iveric - Archemix - Patent Assignment (FULLY EXECUTED)#page7.tif  
source=Iveric - Archemix - Patent Assignment (FULLY EXECUTED)#page8.tif  
source=Iveric - Archemix - Patent Assignment (FULLY EXECUTED)#page9.tif  
source=Iveric - Archemix - Patent Assignment (FULLY EXECUTED)#page10.tif  
source=Iveric - Archemix - Patent Assignment (FULLY EXECUTED)#page11.tif  
source=Iveric - Archemix - Patent Assignment (FULLY EXECUTED)#page12.tif

**Appendix B**

**Patent Assignment**

Archemix LLC (as successor to Archemix Corp.), a Delaware limited liability company with an address at 950 17<sup>th</sup> Street, Suite 1400, Denver, CO 80202 (referred to, together with its successors and assigns, as “**Archemix**”) owns the patents and patent applications listed in the attached Schedule A (referred to collectively as “the **Patents**”).

**Archemix** desires to transfer all right, title, and interest in and to the **Patents** to IVERIC bio., Inc., a Delaware corporation with a place of business at 8 Sylvan Way, Parsippany, NJ 07054 (referred to, together with its successors and assigns, as “**Iveric**”).

**Iveric** desires to acquire all right, title, and interest in and to the **Patents** from **Archemix**.

**Archemix** and **Iveric** therefore agree that:

(1) **Assignment.** For the sum of ten dollars and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, **Archemix** hereby assigns and sells to **Iveric** all of **Archemix**'s right, title, and interest in and to the **Patents** throughout the world. This assignment includes, without limitation, all files, documentation, records, specifications, emails, letters, diagrams, spreadsheets, and the like relating to the **Patents**; all further patents that issue from any one or more of the **Patents**; all rights to claim the priority date under United States law, the Patent Cooperation Treaty, and/or other international arrangements of any earlier United States or other applications; all rights to sue, to bring any cause of action, and to enforce, including all rights to recover damages, injunctive relief, and other remedies for past, present, and future infringements of any of the foregoing; all rights to collect royalties and other payments under or on account of the **Patents**; any and all other rights and interests arising out of, in connection with, or in relation to the **Patents**; and/or all inventions that any one or more of the **Patents** disclose; the same to be held and enjoyed by **Iveric** entirely as if the same would have been held and enjoyed by **Archemix** had this sale and assignment not been made.

(2) **Miscellaneous.** If any part of this Assignment shall be held by a court of competent jurisdiction to be void, invalid, or inoperative, the remaining provisions of this Assignment shall not be affected and shall continue in effect, and the invalid provision shall be deemed modified to the least degree necessary to remedy such invalidity.

*[Signature page follows]*

**EXECUTION VERSION  
CONFIDENTIAL**

In testimony whereof, **Archemix** has executed and delivered this Assignment on the date indicated below.

**Archemix:**

Effective Date: August 31, 2023

**ARCHEMIX LLC  
By Its Sole Member and Manager  
Archemix Liquidating Trust, u/d/t November 22, 2011**

By: Kenneth M. Bate  
Name: Kenneth M. Bate  
Title: Trustee

**Acknowledged and Agreed:**

**Iveric:**

**IVERIC bio., Inc.**

By: Pravin U. Dugel  
Name: Pravin U. Dugel, MD  
Title: President

(The remainder of this page is blank.)

*[Signature page to patent assignment.]*

**Appendix A**  
**Patents**

<b>Title</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Publication No.</b>	<b>Publication Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Country</b>	<b>Status</b>
Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders	2006214437	February 14, 2006			2006214437	April 18, 2013	Australia	Issued
Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders	P106070027	February 14, 2006		May 19, 2020	P106070027	June 22, 2021	Brazil	Issued
Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders	2597889	February 14, 2006			2597889	November 10, 2015	Canada	Issued
Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders	2897900	February 14, 2006			2897900	March 13, 2018	Canada	Issued
Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders	2992874	February 14, 2006			2992874	August 3, 2021	Canada	Issued
Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders	3124030	February 14, 2006					Canada	Pending

A-1

**EXECUTION VERSION  
CONFIDENTIAL**

<b>Title</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Publication No.</b>	<b>Publication Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Country</b>	<b>Status</b>
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	200680011934.9	February 14, 2006			ZL200680011934.9	July 24, 2013	China	Issued
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	201410685384.5	February 14, 2006			ZL201410685384.5	February 23, 2018	China	Issued
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	201810051401.8	February 14, 2006	108148840A	June 12, 2008	ZL201810051401.8	September 24, 2021	China	Issued
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	5713496.7	February 14, 2005			1727567	July 3, 2013	European Patent Convention	Issued
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	6735059.5	February 14, 2006			1850880	November 27, 2013	European Patent Convention	Issued
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	13150168.6	February 14, 2005			2578683	November 26, 2014	European Patent Convention	Issued
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	14194459.5	February 14, 2005	2860251	April 15, 2005	2860251	April 11, 2018	European Patent Convention	Issued

**EXECUTION VERSION  
CONFIDENTIAL**

<b>Title</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Publication No.</b>	<b>Publication Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Country</b>	<b>Status</b>
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	18156968.2	February 14, 2005	3385384 A1	October 10, 2018	3385384	April 8, 2020	European Patent Convention	Issued
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	20168481.8	February 14, 2005	3736335	November 11, 2020			European Patent Convention	Published
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	8104661.2	February 14, 2006			1110329	March 28, 2014	Hong Kong	Issued
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	13111168.8	February 14, 2005			1183896	September 25, 2015	Hong Kong	Issued
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	14101736.1	February 14, 2006					Hong Kong	Pending
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	15108165.5	February 14, 2006					Hong Kong	Pending
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	15109786.2	February 14, 2005	1210495A	April 22, 2016	HK1210495	July 5, 2019	Hong Kong	Issued

**EXECUTION VERSION  
CONFIDENTIAL**

<b>Title</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Publication No.</b>	<b>Publication Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Country</b>	<b>Status</b>
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	18115872.1	December 11, 2018					Hong Kong	Pending
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	42021030932.4	February 14, 2005	40040717	August 6, 2021			Hong Kong	Published
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	3208/KOLNP/2007	February 14, 2006			281057	March 6, 2017	India	Issued
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	185312	February 14, 2006			185312	August 31, 2013	Israel	Issued
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	226339	February 14, 2006			226339	September 1, 2018	Israel	Issued
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	2006-553313	February 14, 2005			5242918	April 12, 2013	Japan	Issued
Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	2007-553346	February 14, 2006			5253818	April 26, 2013	Japan	Issued

A-4



**EXECUTION VERSION  
CONFIDENTIAL**

<b>Title</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Publication No.</b>	<b>Publication Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Country</b>	<b>Status</b>
Apilamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	10-2007-7021243	February 14, 2006			1374931	March 10, 2014	Korea	Issued
Apilamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	10-2014-7002345	February 14, 2006			1622490	May 12, 2016	Korea	Issued
Apilamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	J/3089	May 14, 2018	38	September 19, 2018	J/3089	February 14, 2006	Macau	Issued
Apilamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	MX/a/2010/011135	February 14, 2006			300181	June 7, 2012	Mexico	Issued
Apilamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	560804	February 14, 2006			560804	December 7, 2010	New Zealand	Issued
Apilamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	2007134212	February 14, 2006			2406507	December 20, 2010	Russian Federation	Issued
Apilamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	200705949-6	February 14, 2006			134723	August 31, 2010	Singapore	Issued

**EXECUTION VERSION  
CONFIDENTIAL**

<b>Title</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Publication No.</b>	<b>Publication Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Country</b>	<b>Status</b>
Aplamer Therapeutics Useful In The Treatment Of Complement-Related Disorders	2007/07191	February 14, 2006			2007/07191	July 30, 2008	South Africa	Issued
Aplamer Therapeutics Useful in the Treatment of Complement-Related Disorders	11/058,134	February 14, 2005	2006/0018871	January 26, 2006	7,803,931	28-Sep-2010	US	Issued
Aplamer Therapeutics Useful in the Treatment of Complement-Related Disorders	11/318,227	December 22, 2005	2006/0105980	May 18, 2006	7,538,211	May 26, 2009	US	Issued
Aplamer Therapeutics Useful in the Treatment of Complement-Related Disorders	11/354,657	February 14, 2006	2007/0048248	March 1, 2007	7,579,456	August 25, 2009	US	Issued
Aplamer Therapeutics Useful in the Treatment of Complement-Related Disorders	11/884,411	August 26, 2008	2011/0060027	March 10, 2011	8,236,773	August 7, 2012	US	Issued
Aplamer Therapeutics Useful in the Treatment of Complement-Related Disorders	13/525,680	June 18, 2012	2012/0322860	December 20, 2012	8,436,164	May 7, 2013	US	Issued
Aplamer Therapeutics Useful in the Treatment of Complement-Related Disorders	14/573,423	December 17, 2014	2015/0159158	June 11, 2015	9,617,546	April 11, 2017	US	Issued

**EXECUTION VERSION  
CONFIDENTIAL**

<b>Title</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Publication No.</b>	<b>Publication Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Country</b>	<b>Status</b>
Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders	16/289,374	February 28, 2019	2019/0185858	June 20, 2019	10,947,544	March 16, 2021	US	Issued
Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders	17/200,536	March 12, 2021	2021/0332361	October 28, 2021			US	Published
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	2007223796	March 8, 2007			2007223796	May 9, 2013	Australia	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	2016204713	March 8, 2007			2016204713	November 23, 2017	Australia	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	2022202115	March 8, 2007					Australia	Pending
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	PI0708588-5	March 8, 2007	2444	November 7, 2017			Brazil	Published
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	2643951	March 8, 2007	2643951	September 13, 2007	2643951	March 5, 2019	Canada	Issued

A-7

**EXECUTION VERSION  
CONFIDENTIAL**

<b>Title</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Publication No.</b>	<b>Publication Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Country</b>	<b>Status</b>
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	3009846	March 8, 2007			3009846	August 31, 2021	Canada	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	3148917	February 22, 2022					Canada	Pending
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	201510087938.6	March 8, 2007					China	Pending
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	7752702.6	March 8, 2007			1991275	November 5, 2014	European Patent Convention	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	12173138.4	March 8, 2007			2596807	December 16, 2015	European Patent Convention	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	17206695.3	March 8, 2007	3360582A1	August 15, 2018			European Patent Convention	Published
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	22194830.0	March 8, 2007					European Patent Convention	Pending

**EXECUTION VERSION  
CONFIDENTIAL**

<b>Title</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Publication No.</b>	<b>Publication Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Country</b>	<b>Status</b>
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	9104551.4	March 8, 2007			1127281	September 25, 2015	Hong Kong	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	I3108606.4	March 8, 2007			1181308	August 12, 2016	Hong Kong	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	193828	March 8, 2007			193828	July 1, 2015	Israel	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	2008-558415	March 8, 2007			5406534	November 8, 2013	Japan	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	2013-004412	March 8, 2007			5746232	May 15, 2015	Japan	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	10-2008-7024533	March 8, 2007			1513308	April 13, 2015	Korea	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	10-2014-7014128	March 8, 2007			1584468	January 5, 2016	Korea	Issued

A-9

**EXECUTION VERSION  
CONFIDENTIAL**

<b>Title</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Publication No.</b>	<b>Publication Date</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Country</b>	<b>Status</b>
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	MX/a/2008/011323	March 8, 2007			305756	December 4, 2012	Mexico	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	2008139901	March 8, 2007			2477137	March 10, 2013	Russian Federation	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	2011041449	March 8, 2007			172686	March 8, 2017	Singapore	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	2014011290	March 8, 2007			2014011290	August 31, 2017	Singapore	Issued
Complement Binding Aptamers And Anti-C5 Agents Useful In The Treatment of Ocular Disorders	2008/07620	March 8, 2007			2008/07620	December 30, 2009	South Africa	Issued

A-10